ロード中...
Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)
OBJECTIVES: Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline. METHODS: A prospective, randomised, 6-month, 3-arm, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-contro...
保存先:
| 出版年: | Ann Rheum Dis |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Annals of the Rheumatic Diseases
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5561371/ https://ncbi.nlm.nih.gov/pubmed/28533290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-210860 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|